{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:14:19Z","timestamp":1784733259727,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>This study aimed to analyze four current pathways affecting the listing and post-listing prices of new orphan drugs (ODs) in South Korea. These mechanisms were: (1) essential OD, (2) pharmacoeconomic evaluation (PE) waiver OD, (3) weighted average price OD, and (4) PE OD. We analyzed the ratio of the listing price of 48 new ODs to the average adjusted price (AAP) of seven advanced countries and examined the change in the post-listing price. Descriptive statistics were used to analyze the listing and post-listing price changes. The mean and median ratios of the listing price of total new OD to AAP were calculated to be 69.4% and 65.4%, respectively. Essential OD showed the highest mean (93.8%) and median (80.8%) ratios. The mean cumulative price discount rate of the new OD was 7.2% in the third year and 5.7% in the fifth year. The rarity of diseases impacts the listing price of OD, but the political effects of the benefits of OD on the post-listing price of these drugs could not be verified. Further research should be conducted to develop measures that facilitate the practical sharing of budget risks and increase patient access to new ODs.<\/jats:p>","DOI":"10.3390\/healthcare9030296","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T12:12:18Z","timestamp":1615205538000},"page":"296","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-8879","authenticated-orcid":false,"given":"Jong Hyuk","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Engineering, College of Life and Health Sciences, Hoseo University, Asan 31499, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2017.10.012","article-title":"Marketing Authorisation of Orphan Medicines in Europe from 2000 to 2013","volume":"23","author":"Hofer","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","article-title":"Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report","volume":"20","author":"Benjamin","year":"2017","journal-title":"Value Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.clinthera.2019.10.006","article-title":"Orphan Medicines for Pediatric use: A Focus on the European Union","volume":"41","author":"Bolislis","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kimmel, L., Conti, R.M., Volerman, A., and Chua, K.P. (2020). Pediatric Orphan Drug Indications: 2010-2018. Pediatrics, 145.","DOI":"10.1542\/peds.2019-3128"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","article-title":"Orphan Drugs: Major Development Challenges at the Clinical Stage","volume":"24","author":"Fonseca","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-019-1017-5","article-title":"Regulatory Strategies for Rare Diseases under Current Global Regulatory Statutes: A Discussion with Stakeholders","volume":"14","author":"Mulberg","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hughes, D.A., and Poletti-Hughes, J. (2016). Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164681"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.drudis.2012.02.005","article-title":"Orphan Drug Development: An Economically Viable Strategy for Biopharma R&D","volume":"17","author":"Meekings","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2019.00487","article-title":"Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries","volume":"10","author":"Malinowski","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-019-1078-5","article-title":"Comparing Access to Orphan Medicinal Products in Europe","volume":"14","author":"Zamora","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lee, S.H., Yoo, S.L., Bang, J.S., and Lee, J.H. (2020). Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007\u20132019). Int. J. Environ. Res. Public. Health, 17.","DOI":"10.3390\/ijerph17092991"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-6-62","article-title":"Estimating the Budget Impact of Orphan Medicines in Europe: 2010\u20132020","volume":"6","author":"Schey","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","article-title":"Drug Discovery and Development for Rare Genetic Disorders","volume":"173","author":"Sun","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/erp.11.95","article-title":"Access to Orphan Drugs in Europe: Current and Future Issues","volume":"12","author":"Michel","year":"2012","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-9-62","article-title":"Shining a Light in the Black Box of Orphan Drug Pricing","volume":"9","author":"Picavet","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1297886","DOI":"10.1080\/20016689.2017.1297886","article-title":"A Comparative Study of Orphan Drug Prices in Europe","volume":"5","author":"Young","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yoo, S.L., Kim, D.J., Lee, S.M., Kang, W.G., Kim, S.Y., Lee, J.H., and Suh, D.C. (2019). Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System. Int. J. Environ. Res. Public. Health, 16.","DOI":"10.3390\/ijerph16020288"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14737167.2020.1758559","article-title":"The Current State of Patient Access to New Drugs in South Korea under the Positive List System: Evaluation of the Changes since the New Review Pathways","volume":"21","author":"Kim","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hec.931","article-title":"The Impact of Price Regulation on the Launch Delay of New Drugs\u2014Evidence from Twenty-Five Major Markets in the 1990s","volume":"14","author":"Danzon","year":"2005","journal-title":"Health Econ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10198-019-01116-4","article-title":"Does External Reference Pricing Deliver what it Promises? Evidence on its Impact at National Level","volume":"21","author":"Kanavos","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Remuzat, C., Urbinati, D., Mzoughi, O., El Hammi, E., Belgaied, W., and Toumi, M. (2015). Overview of External Reference Pricing Systems in Europe. J. Mark. Access Health Policy, 3.","DOI":"10.3402\/jmahp.v3.27675"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1369817","DOI":"10.1080\/20016689.2017.1369817","article-title":"The Perverse Impact of External Reference Pricing (ERP): A Comparison of Orphan Drugs Affordability in 12 European Countries. A Call for Policy Change","volume":"5","author":"Young","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kim, S., and Lee, J.H. (2020). Price-Cutting Trends in New Drugs After Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction. Healthcare, 8.","DOI":"10.3390\/healthcare8030233"},{"key":"ref_25","unstructured":"Ministry of Health and Welfare (2021, February 10). Criteria for Decision or Adjustment on Drugs. Available online: https:\/\/www.law.go.kr\/admRulSc.do?menuId=5&subMenuId=41&tabMenuId=183#liBgcolor11."},{"key":"ref_26","unstructured":"Health Insurance Review and Assessment Service (2021, February 10). Publication of Results Evaluated by the Drug Reimbursement Evaluation Committee. Available online: https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014040000."},{"key":"ref_27","unstructured":"Health Insurance Review and Assessment Service (2021, February 10). Information of Reimbursement History. Available online: https:\/\/www.hira.or.kr\/rf\/medicine\/getHistoryList.do?pgmid=HIRAA030035020000."},{"key":"ref_28","first-page":"1","article-title":"Trends in the Pricing and Reimbursement of New Anticancer Drugs in South Korea: An Analysis of Listed Anticancer Drugs during the Past Three Years","volume":"17","author":"Kim","year":"2020","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gammie, T., Lu, C.Y., and Babar, Z.U. (2015). Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140002"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1601060","DOI":"10.1080\/20016689.2019.1601060","article-title":"Government Pharmaceutical Pricing Strategies in the Asia-Pacific Region: An Overview","volume":"7","author":"Verghese","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.healthpol.2016.07.017","article-title":"Assessment of the Price-Volume Agreement Program in South Korea","volume":"120","author":"Han","year":"2016","journal-title":"Health Policy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s41669-017-0044-1","article-title":"Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends","volume":"2","author":"Piatkiewicz","year":"2018","journal-title":"Pharmacoecon. Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.healthpol.2016.03.013","article-title":"Eight-Year Experience of using HTA in Drug Reimbursement: South Korea","volume":"120","author":"Bae","year":"2016","journal-title":"Health Policy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.healthpol.2011.09.006","article-title":"Evaluation on the First 2 Years of the Positive List System in South Korea","volume":"104","author":"Park","year":"2012","journal-title":"Health Policy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1299665","DOI":"10.1080\/20016689.2017.1299665","article-title":"Do Payers Value Rarity? an Analysis of the Relationship between Disease Rarity and Orphan Drug Prices in Europe","volume":"5","author":"Medic","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-018-0667-9","article-title":"Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?","volume":"36","author":"Mattingly","year":"2018","journal-title":"Pharmacoeconomics"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/9\/3\/296\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:34:58Z","timestamp":1760160898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/9\/3\/296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["healthcare9030296"],"URL":"https:\/\/doi.org\/10.3390\/healthcare9030296","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}